Eli Lilly will partner with Nimbus Therapeutics to develop an oral treatment for obesity and other metabolic diseases, through a multi-year research collaboration and exclusive worldwide license ...

The weight loss drug Wegovy is now available as a tablet in more than 70,000 U.S. pharmacies as well as select telehealth ...

Americans seeking to lose weight now have a new option – taking Wegovy as a daily pill, rather than a weekly injection.

Arrowhead Pharmaceuticals said Tuesday its gene-silencing approach almost doubled the four-month weight-loss with tirzepatide ...

The convenience and lower cost of the oral pill may be critical to some patients, which could expand the market, improve ...

Eli Lilly and Company rated Buy: incretin/obesity growth, ZEPBOUND & orforglipron access strategy, pipeline deals, ...

Eli Lilly and Nimbus Therapeutics have entered into a multi-year collaboration and exclusive licensing agreement to develop an oral treatment for obesity and other metabolic diseases. Nimbus, an ...

Privately-held Boston, USA-based Nimbus Therapeutics today announced it has entered into a multi-year research collaboration ...

A daily pill for weight loss has officially arrived in the U.S. On Monday, Novo Nordisk rolled out the first GLP-1 ...

It’s the latest move in the race by drug companies to corner more of the highly-lucrative obesity drug market.

The pill was approved by the U.S. Food and Drug Administration last month, a boon to Novo Nordisk as it looks to regain ...

Novo Nordisk shares jump after the U.S. launch of its FDA-approved Wegovy pill, giving the first oral GLP-1 weight-loss drug ...